Journal of Diabetes

Author Guidelines

1. MANUSCRIPT SUBMISSION

Thank you for your interest in Journal of Diabetes. Please read the complete Author Guidelines carefully prior to submission. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Free Format submission

Journal of Diabetes now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

• Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract (which does need to be correctly styled), introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.
• An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)
• A cover letter
• The title page of the manuscript, including:
  • Your co-author details, including affiliation and email address. If applicable, institutional affiliation, including institutional email addresses are strongly encouraged. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
  • Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):
    • data availability statement
    • funding statement
    • conflict of interest disclosure
    • ethics approval statement
    • patient consent statement
    • permission to reproduce material from other sources
    • clinical trial registration

To submit, login at https://wiley.atyponrex.com/journal/JDB and create a new submission. Follow the submission steps as required and submit the manuscript.

The submission system will prompt you to use an ORCiD (a unique author identifier) to help distinguish your work from that of other researchers. Click here to find out more.

We are looking forward to your submission.

Preprints

Please find our preprint policy here.
This journal accepts articles previously published on preprint servers. You are requested to update any pre-publication versions with a link to the final published article. You may also post the final published version of the article immediately after publication.

Refer and Transfer Program

Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant.

2. EDITORIAL CONSIDERATIONS

Aims and Scope
Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation.

The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and we solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.

Effective with the 2017 volume, this journal will be published in an online-only format.

Print subscription and single issue sales are available from Wiley’s Print-on-Demand Partner. To order online click through to the ordering portal from the journal’s subscribe and renew page on WOL.

Review Process

JDB adopts single anonymised peer review. In order to assure full assessment all manuscripts are reviewed by three members of the editorial group and a decision is made whether to send for external review within 2 weeks. Manuscripts are assigned sequentially to Associate Editors. An Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations are compiled by the Editors for disposition and transmittal to the authors. A decision is made usually within 6 weeks of the receipt of the manuscript.

The Editors will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within four weeks of decision; major revisions within three months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.

A number of manuscripts will have to be rejected on the grounds of priority and available space.A manuscript may be returned to the authors without outside review if the Editors find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.

For manuscripts of exceptional scientific quality, novelty, and urgency, the Editors-in-Chief may, at their discretion, offer a fast-track review process. This option is intended to facilitate the timely dissemination of high-impact research and follows the same standards as the regular review process. The Editor will invite reviewers who can deliver high-quality reviews within a short timeframe.

The Editors' decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editorial Office. Resubmission of a rejected manuscript will not be considered unless significant additional work is completed, authors should contact the Editorial Office first and include a concise statement of the specific reason for resubmission.

In-house submissions, i.e. papers authored by Editors or Editorial Board members of the title, will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias. Members of the Editorial Board who submit manuscripts to the journal are blinded to the peer review process and excluded from editorial decision-making on their own work to minimise bias.

Mendelian Randomization Studies. In general, the journal will not publish Mendelian randomization studies unless the genetic factor being investigated is uniquely associated with the medical characteristics being queried. Mendelian randomization studies should be accompanied by the completed STROBE checklist available at at the STROBE-MR website. The checklist should be uploaded as a supplemental file. Studies that do not comply with all the checklist requirements will not be considered. The checklist will not be transmitted to Production, should the manuscript be accepted.

Existing Large Database Studies. The journal will not consider studies based on existing large databases (e.g., NHANES, UK Biobank, etc.) if similar analyses have been previously performed or reported.

Bioinformatics Studies. The journal will not consider studies on bioinformatic analysis without verifications

3. ETHICAL CONSIDERATIONS

Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for important intellectual content; iii) Final approval of the version to be published; and iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.

The journal accepts up to three corresponding authors, but please appoint one as the main contact to communicate with editors.

Disclosure
At the time of submission, the submitting author must include a disclosure statement in the body of the manuscript. All authors are required to disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. This information should be provided under the heading titled ‘Disclosure,’ which should appear after the ‘Acknowledge’ section and before the ‘References’ section. Authors without conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript. The conflict of interest policy for the Editors is available on the journal's Editors Conflict Guidelines.

Principles for Publication of Research Involving Human Subjects
Manuscripts must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki (as revised in Brazil 2013), available at https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under the study should be omitted. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).

In general, submission of a case report should be accompanied by the written consent of the subject (or parent/guardian) before publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editorial Board recognizes that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case.

Any experiments involving animals must be demonstrated to be ethically acceptable and must conform to international guidelines for animal usage in research, such as those of the US NIH or the UK Home Office.

Clinical Trials Registry
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt.

We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian New Zealand Clinical Trials Registry (ANZCTR); (4) the Chinese Clinical Trials Registry; and (5) the Clinical Trials Registry - India.

Randomized control trials
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement, and the CONSORT Checklist is required to be uploaded as supplementary information during submission.

Reproduction of Copyright Material. If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at http://exchanges.wiley.com/authors/faqs---copyright-terms--conditions_301.html

Plagiarism Detection. The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

Committee on Publication Ethics. The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).

AI Policy. Artificial Intelligence Generated Content (AIGC) tools—such as ChatGPT and others based on large language models (LLMs)—cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for research design, which is a generally held requirement of authorship (as discussed in the previous section), nor do they have legal standing or the ability to hold or assign copyright. Therefore—in accordance with COPE’s position statement on AI tools—these tools cannot fulfill the role of, nor be listed as, an author of an article. If an author has used this kind of tool to develop any portion of a manuscript, its use must be described, transparently and in detail, in the Methods or Acknowledgements section. The author is fully responsible for the accuracy of any information provided by the tool and for correctly referencing any supporting work on which that information depends. Tools that are used to improve spelling, grammar, and general editing are not included in the scope of these guidelines. The final decision about whether use of an AIGC tool is appropriate or permissible in the circumstances of a submitted manuscript or a published article lies with the journal’s editor or other party responsible for the publication’s editorial policy.

4. MANUSCRIPT CATEGORIES

(1) Original Articles

• Word limit: 4,000 words maximum including abstract but excluding the highlights of the study (see 5. PREPARATION OF THE MANUSCRIPT, under Highlights), references, tables and figures.
• Abstract: 250 words maximum, with sub-headers.
• References: no limit.
• Figures/ tables: no limit, but 8 figures should be sufficient.
• Description: Full-length reports of current research in either basic or clinical science.

(2) Case Reports

• Word limit: 1,000 words maximum excluding references, tables and figures.
• Abstract: not required.
• References: no limit.
• Figures/ tables: 4 maximum.
• Description: New observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in diabetes. The text should be arranged as follows: Introduction; Case Report; Discussion. Such cases would be expected to illustrate highly unusual demonstrations of diabetes-related principals, such as genetic or hormonal variations, which would not be expected to occur with sufficient frequency to be demonstrable in the setting of a clinical trial or population study.

(3) Point-Counterpoint

• Title: 10 words maximum.
• Word limit: 700 words maximum.
• Abstract: not required.
• References: No limit.
• Figures: 2 maximum.
• Description: Balanced discussion of controversies in pathology.

(4) Letters to the Editor

• Word limit: 500 words maximum.
• Abstract: not required.
• References: No limit.
• Figures/ tables: 1 maximum.
• Description: Letters must offer perspective to content published in JDB. A Letter must reference the original source, and a Response to a Letter must reference the Letter in the first few paragraphs. Letters can use an arbitrary title, but a Response must cite the title of the Letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion. Authors to whom the letter type is referred for submission by the Editor are exempt in adherence to the scope of the letter type.

(5) Commentaries

• Word limit: 1,500 words maximum excluding references.
• Title: 20 words maximum.
• Abstract: not required.
• References: 20 maximum, including the article discussed.
• Figures/tables: 2 maximum.
• Description: Commentaries discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field.

(6) Review Articles

• Word limit: 3000-5,000 words including abstract but excluding the highlights of the study (see 5. PREPARATION OF THE MANUSCRIPT, under Highlights), references, tables and figures
• Abstract: 250 words maximum, sub-headers are not required.
• References: no maximum.
• Figures/tables: minimum 1 image or figure.
• Description: Reviews are comprehensive analyses of specific topics. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

(7) Research Letters

• Word limit: 800 words maximum but excluding the highlights of the study (see 5. PREPARATION OF THE MANUSCRIPT, under Highlights).
• Abstract: none.
• References: No limit.
• Figures/tables: 2 maximum.
• Description: Research Letters should report original findings in an intermediate fashion between an abstract and an article. These submissions must not duplicate other material published or submitted for publication. In general, Research Letters should be divided into the following sections: To the Editor (which serves as an introduction), Methods, Results, and Comment. Research Letters considered for publication will undergo peer review.

(8) Editorials [by invitation of Editors]

• Word Limit: 1,500 words maximum.
• Abstract: not required.
• References: No limit.
• Description: Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.

(9) Meeting Abstracts [by invitation of Editors]

• Word limit: 400 words maximum.●  Funding and disclosure information are required.
• Figures/Tables: 1 maximum.
• Description: Only accepted abstracts from prestigious conferences or symposiums will be considered if proposed by the conference organizer. And it needs to get approval from Chief editors and editorial office. 
  
  

(10) News Articles [by invitation of Editors]

• Word limit: 2,000 words maximum.
• Abstract: Not required.
• Figures/Tables: No limit.
• References: No limit
• Description: External factual information to keep readers up to date with events, written by editors, editorial Board members, or invited authors.

(11) Guideline/Consensus

• Word limit: 5,000 words maximum including abstract but excluding references, tables and figures.
• Abstract: 250 words maximum, sub-headers are not required.
• Figures/Tables: minimum 1 image or figure.
• References: no limit.
• Description: Public statement of what a representative group of experts agree to be evidence-based and state-of-the-art knowledge on an aspect of practice/policy.

(12) Correspondence

• Word limit: 1,500 words maximum.
• Abstract: not required.
• Figures/Tables: 1 maximum.
• References: no limit.
• Description: A letter, or response to a letter, sent to the journal to raise a point of interest, discuss a difference of opinion or encourage participation.

5. PREPARATION OF THE MANUSCRIPT

Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author.  Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.

Optimising Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.

Style of the Manuscript
Manuscripts must follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors’ revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication.

Author name: Each author’s name should be put in the following order:
First and Middle names (given name, capitalize the first letter of each name)
Last name (family name, surname, all letters should be capitalized)

Spelling: The journal uses US spelling and authors should therefore follow the latest edition of Merriam–Webster’s Collegiate Dictionary.

Units: All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website.

Abbreviations: Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Trade names: Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Parts of the Manuscript

The manuscript should be submitted in separate files: title page; main text file; figures; and supplementary files if required.

Highlights
The Highlights are usually drawn from the conclusion of the study, in two to three sentences, 80 words maximum, sub-headers are not required.

Title Page File
The title page should contain (i) the title and running title (less than 40 characters) of the paper. Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized controlled trials). Authors should include all information in the title that will make electronic retrieval of the article both sensitive and specific. (ii) the full names of the authors (for details on how to present the Author names see the section on Style of the Manuscript) and (iii) the addresses of the institutions at which the work was carried out together with (iv) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent. The journal accepts up to three corresponding authors, but please appoint one as the main contact to communicate with editors. The present address of any author, if different from that where the work was carried out, should be supplied in a footnote. The title should be short, informative and contain the major key words so that readers and in particular online users will discover the article easily in online search. In general, abbreviations should not be used in the title.

Main Text File
The main text file should be presented in the following order: (i) Abstract, (ii) Highlights, (iii) Key words (iv) Text, (v) Acknowledgments, (vi) Disclosure, (vii) References, (viii) Figure legends, and (ix) Tables (each table complete with title and footnotes). Figures and supplementary material should be supplied as separate files, with the heading "supplementary material" included at the beginning of any supplementary information.

Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

Abstract
The length of abstracts must adhere to the word count specifications under the section Manuscript Categories. Original article abstracts should be structured using the following subheadings: Background, Methods, Results, and Conclusions. Other manuscript types do not require structured abstracts and therefore do not require subheadings. Abstracts must be factual and comprehensive. The use of abbreviations and acronyms should be limited and general statements (e.g. ‘‘the significance of the results is discussed’’) should be avoided.

Graphical Abstract
JDB provides the options for authors to publish graphical abstract for Original Articles, Review Articles and Research Letters, displayed online in graphical form with a brief abstract (in addition to the abstract above).

The online table of contents will display a schematic figure to convey the core message of your paper, alongside a short abstract highlighting the major findings of the paper. Authors should submit a new and stand-alone image, not already included in the paper. Your graphical abstract should be simple, colourful and contain minimal text to attract additional readers. Graphical abstract entries should be submitted to ScholarOne in one of the generic file formats and uploaded as ‘Graphical Abstract’ during the initial manuscript submission process. The image should be supplied as a tif or a pdf and fit within the dimensions of 50mm x 60mm, and be fully legible at this size. We will also publish the graphical abstract on the first page of your articles to attract readership, however, please note that only the most appropriates ones will be selected by the editors.

Keywords
Three to five key words should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list.

Text
Authors must use the following subheadings to divide the sections of their Original Article manuscript: Introduction, Methods, Results, Discussion.

Acknowledgements
This should include sources of support/funding, including federal and industry support. All authors who have contributed to the manuscript must be acknowledged any federal and industry support/funding received. Medical writers, proofreaders and editors should not be listed as authors, but acknowledged here in this section.

Disclosure
All articles are required to include a disclosure statement. The statement should disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. Authors without conflicts of interest should include a statement of no such interests in the Disclosure section of the manuscript. This information should be provided under the heading titled ‘Disclosure,’ which should appear after the ‘Acknowledgements’ section and before the ‘References’ section. Failure to include this information in the manuscript may delay evaluation and review of the manuscript. The journal also has an Editorial Conflict of Interest Policy available for viewing via the journal's Editors Conflict Guidelines.

References
All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. Sample references follow:

• Journal Article
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol. 1998;390:537-551.

• Book
3. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.

For more information about AMA reference style - AMA Manual of Style

Tables
Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure legends
Type figure legends on a separate page after References or Tables if the manuscript includes them. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration.

• Size - Figures should be sized to fit within the column (82mm), intermediate (118mm) or the full text width (173mm).

• Text sizing in figures - Lettering must be included and should be sized to be no larger than the journal text or 8 point (Should be readable after reduction – avoid large type or thick lines). Line width between 0.5 and 1 point.

• Each figure should be supplied as a separate file, with the figure number incorporated in the file name and also showing within the figure. For submission, high-resolution figures (at least 300 d.p.i. for images, 600 d.p.i. for line art) saved as .eps or .tif files should be uploaded.

Preparation of Electronic Figures for Publication: We require high quality images to prevent the final product being blurred or fuzzy, please submit EPS (line art), TIFF (halftone/photographs), or PNG files. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented programmes. Scans (TIFF only) should have a resolution of 300 dpi (halftone) or 600 to 1200 dpi (line drawings) in relation to the reproduction size (see below). EPS files should be saved with fonts embedded (and with a TIFF preview if possible). For scanned images, the scanning resolution (at final image size) should be as follows to ensure good reproduction: line art: >600 dpi; half-tones (including gel photographs): >300 dpi; figures containing both halftone and line images: >600 dpi.

Supporting Information
Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted with your manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found at: http://authorservices.wiley.com/bauthor/suppmat.asp

Please note that the provision of supporting information is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.

Article Preparation Support
Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

6. SUBMISSION REQUIREMENTS

Manuscripts must be submitted online at: http://mc.manuscriptcentral.com/jdb

A cover letter should be included in the ‘Cover Letter Field’ of the ScholarOne system. The text can be entered directly into the field or uploaded as a file.

The cover letter must contain: i) A statement confirming the paper has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium; ii) An acknowledgment that all authors have contributed significantly and in keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be described, i.e., what role each author participated in; iii) a statement confirming that all authors are in agreement with the content of the manuscript

Two Word-files need to be included upon submission: A title page file and a main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including tables and figure legends but excluding figures which should be supplied separately.

The main text file should be prepared using Microsoft Word.

Associate your ScholarOne account with your ORCID iD
ORCID iD is a unique and persistent identifier that distinguishes you from every other researcher and connects you and your research activities. We require you to register for an ORCID iD and then associate it with your ScholarOne account. Click here to find out how.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the copyright and licencing options for the journal appear below.

Wiley’s Author Services: Tracking your paper’s progress
Author Services also enables authors to track their article through the production process to publication online. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Visit http://www.authorservices.wiley.com/bauthor/eachecklist.asp for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Proofs
Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Page proofs should be carefully proofread for any copyediting or typesetting errors. Online guidelines are provided within the system. No special software is required, all common browsers are supported. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email. Return of proofs via e-mail is possible in the event that the online system cannot be used or accessed.

Offprints
A PDF reprint of the article will be supplied free of charge to the corresponding author. Additional printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: www.sheridan.com/wiley/eoc. 

Author Marketing Toolkit
The Wiley Author Marketing Toolkit provide authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.

Article Promotion Support
Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Correction to authorship

In accordance with Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and the Committee on Publication Ethics’ guidance, JDB will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the Request for Changes to a Journal Article Author List Form and contact either the journal’s editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. Correcting the authorship is different from changing an author’s name; the relevant policy for that can be found in Wiley’s Best Practice Guidelines under “Author name changes after publication.”

8. OPEN ACCESS, COPYRIGHT AND LICENSING

Journal of Diabetes has joined Wiley’s Open Access portfolio as of January 2022. As a result, all submissions received from 15 September 2021 are subject to an Article Publication Charge if accepted and published in the journal (unless a waiver is applied). While Journal of Diabetes does not charge any submission fees, authors of accepted articles are asked to pay an Article Publication Charge to cover publication costs. Information on the Article Publication Charge for publishing in the journal is here.

Journal of Diabetes is an Open Access journal and accepted articles are published under Creative Commons Attribution License (CC BY). With CC BY, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and to identify as the original publisher. 

If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to login to Author Services, where via the Wiley Author Licensing Service (WALS), they will be able to complete the license agreement on behalf of all authors on the paper.

To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate a particular type of CC license be used; to check this, please click here.

Access and sharing

Please review Wiley’s guidelines on sharing your research here. The submitted version of the manuscript, the accepted version, and the published version (Version of Record) can all be deposited on an institutional or other repository of the author's choice without embargo.

9. STUDY DESIGN SUPPORT
Study Design Support is a free and confidential service by the editorial team at Journal of Diabetes to help you design your studies.

How does it work?
Our editorial team provides you with free and confidential feedback on your study design before you submit your final study to a journal, or before you do the study. Study Design Support does not reject, accept or publish your study design. We just provide you with free and confidential feedback. You submit your study design to us, using a submission form.

How long does the feedback take?
The Editors try to complete feedback on your study designs within two weeks.

Do I have to publish later in Journal of Diabetes if I use Study Design Support?
No. Journal of Diabetes welcomes manuscripts, but submission of your study design to Study Design Support does not condition and does not guarantee publication of a later and related manuscript to the Journal. Instead, Study Design Support just provides you with free and confidential feedback on your study design in advance of submission to any journal. You are free to publish your final manuscript in any journal of your own choice. Read more here.

10. EDITORIAL OFFICE

Dr. Min Cao
Room 1504, Science and Education Plaza
Ruijin Hospital, 197 Ruijin 2nd Road
Shanghai 200025, China
Email: [email protected]
Tel: +86 21 64370045 extn 611566
Fax: +86 21 64151361

Guidelines updated in February 2025